If they don't get it the RS will probably still be rejected and Cox will most likely be fired (followed by an austerity program... and because Atryn looks like such a blockbuster drug they don't really need their other stuff).
More upside then downside short term.
The nightmare sequence is the RS gets approved, followed by the massive dilution (with no partnership), and Cox staying on. But I consider that rather unlikely.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.